Details of the Evaluation Agreement

The newly signed agreement allows Axolabs to assess Codexis' state-of-the-art manufacturing platform, which could lead to future licensing discussions and broader adoption within the industry. This partnership positions both companies to better meet the increasing demand for efficient production of oligonucleotide therapeutics.

Implications for the Oligonucleotide Market

"Part of our mission is to expand the reach of our ECO Synthesis Manufacturing Platform through collaborations with best-in-class CDMOs," said Alison Moore, President & CEO of Codexis. "Axolabs is an industry-leading CRDMO, and we are delighted to enter into this partnership with them to enable more efficient manufacturing of oligonucleotide therapeutics that address large markets."

The collaboration is expected to pave the way for substantial advancements in how therapeutic oligonucleotides are scaled, which could enhance production sustainability and reduce costs, making these vital therapies more accessible globally.

Expert Insights on the Partnership

Kathleen Campau, Senior Director of Operations for Axolabs, highlighted, "This technology has the potential to be pivotal to how therapeutic oligonucleotides are manufactured at scale in the future, enabling more sustainable and cost-effective production." This sentiment underscores both companies' commitment to advancing the science of therapeutic oligonucleotides.

About Codexis, Inc. and Axolabs

• Codexis, Inc.: Codexis specializes in enzymatic solutions that facilitate the efficient manufacturing of therapeutics, leveraging the proprietary CodeEvolver® technology platform. The company is focused on resolving real-world challenges in small molecule pharmaceuticals and nucleic acid synthesis. Its ECO Synthesis Manufacturing Platform aims to enhance the scalable production of RNAi therapeutics.
• Axolabs: Axolabs is a leader in nucleic acid therapeutics, advancing the development and production of RNA-based drugs. Their comprehensive platform spans from early discovery to GMP manufacturing, significantly expediting the journey from innovation to patient delivery.

A Promising Future for Therapeutics

The collaboration between Codexis and Axolabs reinforces a shared objective to enhance access to high-quality oligonucleotide-based medicines worldwide. The potential impact of the ECO Synthesis Manufacturing Platform on the industry could reshape therapeutic options for patients, bringing cutting-edge solutions to the forefront.